Hemophilia A and B Recombinant Therapeutics Market to Rise due to Rising Utilization of Routine Prophylaxis


Published Date : Apr 04, 2016

ALBANY, New York, April 04, 2016 - MarketResearchReports.biz has added the ‘PharmaPoint: Hemophilia A And B Recombinant Factor Replacement Therapy - Global Drug Forecast And Market Analysis To 2024’ report to its offering. This study on the market for hemophilia recombinant therapeutics comprises the future and the current market competitive scenario. It also provides an insightful review on the prime factors fuelling as well as restraining the growth of the market. The prevalent trends, unmet needs, and the key opportunities within the market have also been evaluated under this study. The report helps in the designing and developing of out-licensing and in-licensing strategies by providing a review of the pipeline technologies and products. It also helps identify the major companies having the most lucrative pipelines.

As per the report, the sales in the global hemophilia A and B recombinant therapeutics market were estimated to be US$5.38 bn in 2014 across the 7MM and Argentina and are predicted to reach US$6.25 bn by 2024, expanding at a 1.52% CAGR from 2015 to 2024. The report commences by providing a disease overview and also highlights the pathophysiology, etiology, quality of life of the patients, and prognosis of the disease. Hemophilia A and B are types of bleeding disorders in which the blood clotting process is hampered. People having this disorder experience prolonged bleeding after a surgery, tooth extraction, or any injury.

Moving further, the background of the disease and the risk factors associated with it are being elaborated upon under this study. Serious complications may result in bleeding into the muscles, the brain, joints and other internal organs. In hemophilia, the most important thing is the replacement of the missing FIX or FVIII gene produced utilizing recombinant or plasma-derived methods. Some of the patients may also develop inhibitors to FIX or FVIII treatment and might require a bypassing agent, named FVIIa, for resolving bleeding.

View Full Report at http://www.marketresearchreports.biz/sample/sample/667477

As per the report, the prime factor fuelling the hemophilia A and B recombinant therapeutics market is the rising utilization of routine prophylaxis. In addition, the high usage of recombinant products as an alternative to plasma-derived therapies is also augmenting the growth of the market. On the other hand, as per the study, the negligence of hemophilia A patients in switching to long-acting rFVIII and limited scope of the premium-priced new agents are amongst the prime factors impeding the growth of the market. Moving further, the report also throws light on the product profiles of Hemophilia A and B therapeutics market players, along with providing their pipeline assessment.

In the next section, the report states that a number of companies are focused on the advancement of therapies. Baxalta is predicted to maintain its superiority in the market all through the forecast horizon owing to the present gold standard therapy for treating hemophilia A named Advate, backed by the introduction of its pegylated rFVIII, named Adynovate.

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz